Levetiracetam

Keppra tablets/solution treat partial-onset seizures from age 1 month, as monotherapy or adjunctive therapy. Adjunctive indications are myoclonic seizures with juvenile myoclonic epilepsy from age 12 and primary generalized tonic-clonic seizures with idiopathic generalized epilepsy from age 6. IV Keppra has these indications only as an alternative when oral administration is temporarily infeasible; clinical IV experience beyond 4 days is lacking.

Keppra XR treats partial-onset seizures from age 12; its standard starting regimen is specified for weight≥ 50 kg. Elepsia XR is adjunctive treatment of partial-onset seizures from age 12. Spritam treats partial-onset seizures from age 4 with weight> 20 kg, and adjunctively treats JME myoclonic seizures from 12 and idiopathic generalized tonic-clonic seizures from 6; Spritam is not recommended in children weighing≤ 20 kg. No status-epilepticus loading regimen is supplied by these labels.

These are adult tables using estimated CrCl adjusted for body surface area, not an interchangeable unadjusted eGFR or pediatric algorithm. Printed mild/moderate ranges share 50; the treating team must resolve boundary classification and individualized dose. Elepsia XR provides only> 80: 1000–3000 mg daily and 50–80: 1000–2000 mg daily; it is not recommended for moderate/severe impairment, and dialysis requires an IR alternative. Pediatric renal adjustment data are not supplied in IV labeling; consult pediatric specialists rather than applying adult tables.

IR Keppra may be taken with or without food; swallow tablets whole without chewing/crushing. Use 100 mg/mL oral solution for pediatric weight≤ 20 kg with a calibrated oral measuring device; prescribed mg per dose divided by 100 gives mL per dose. XR tablets must remain whole: never chew, break or crush Keppra XR; never split/cut Elepsia XR. Spritam uses whole tablets only: peel foil with dry hands, place one on tongue and take a sip of liquid, then swallow after dispersal; do not swallow intact. A whole-tablet cup dispersion is also allowed, followed by a residue rinse. Do not independently substitute IR/XR schedules.

For temporary IV Keppra substitution, match the IR oral total daily dose and frequency in either direction. Dilute selected 100 mg/mL concentrate in 100 mL compatible fluid for adults; if smaller volume is required, final concentration must not exceed 15 mg/mL. Infuse over 15 minutes, not an inferred IV-push/loading regimen. Compatible diluents are 0.9% saline, lactated Ringer’s and 5% dextrose. Spritam’s selected tube method is only for NG/G tubes French 10–14: disperse prescribed whole tablets in about 10 mL room-temperature water, administer immediately with 10 mL oral catheter-tip syringe, then twice add 10 mL water to the cup, swirl residue and flush through the same tube. Verify package method and fluid allowances.

Known hypersensitivity to levetiracetam; anaphylaxis and angioedema have occurred. Verify excipients/formulation history when selecting a product.

The selected levetiracetam labels have no boxed warning. Suicidal thoughts/behavior, severe hypersensitivity and withdrawal-related seizures remain important warnings; absence of a box does not remove the need for monitoring.

Common reports include somnolence, weakness/fatigue, dizziness and infection; pediatric reports also include aggression, irritability, appetite reduction and nasal symptoms. Patterns/rates depend on age, seizure indication and formulation trials. Postmarketing reports include cytopenias, severe skin/systemic allergy, liver injury, kidney injury, hyponatremia, movement symptoms and seizure worsening. Overdose can cause agitation/aggression, depressed consciousness, respiratory depression or coma. No specific antidote is known; obtain urgent medical/Poison Help advice, protect airway and monitor clinically. Clinicians may consider hemodialysis, which removes about 50% in 4 hours; do not attempt home emesis.

Levetiracetam is not substantially CYP-metabolized and has low protein binding. Label studies found no relevant interaction with phenytoin, valproate, warfarin, digoxin or the studied ethinyl-estradiol/levonorgestrel contraceptive. This is not proof of no interaction with every drug or hormone product. Pediatric enzyme-inducing antiseizure co-treatment increased apparent clearance about 22%, without a recommended automatic adjustment.

Probenecid reduces clearance of the inactive major metabolite and raises its peak, while parent levetiracetam pharmacokinetics were unchanged; the reverse effect was not studied. Review sedating agents in patients with somnolence/incoordination and monitor clinical impairment. IV compatibility is product-specific: selected Keppra supports lorazepam, diazepam and valproate sodium mixtures, with no compatibility data for other antiseizure agents; do not infer compatibility or stability of another premix.

Renal clearance falls with impairment; use the appropriate adult renal regimen, including IR postdialysis supplement. Elepsia XR has additional restrictions. Older adults need careful selection and renal monitoring. Keppra PK studies found no hepatic-only dose adjustment needed; severe hepatic disease reduced total clearance largely through reduced renal clearance, so still assess kidney function. Other product populations must follow their exact labels.

Prolonged human experience and registry/literature data have not identified a major-birth-defect or miscarriage association, but cannot establish absence of risk; animal developmental toxicity is reported. Levels may fall during pregnancy, especially third trimester; monitor response/levels and continue close postpartum review if dose changed. Discuss pregnancy registry enrollment and the risk of uncontrolled seizures before altering treatment. Levetiracetam enters human milk; selected label lacks infant-effect/milk-production data. Weigh maternal need, feeding benefits and potential infant risk.

IR/IV partial-onset use begins at 1 month; other seizure types and products have different ages. Keppra IR solution is required at weight≤ 20 kg; Spritam is not recommended in children≤ 20 kg despite a dosing-table heading beginning at 20. Keppra XR’s specified standard regimen requires age≥ 12 and weight≥ 50 kg; Elepsia XR is not indicated below 12. Infants/young children need behavioral, growth/development and age-specific BP assessment, with no invented pediatric renal algorithm.

The antiseizure mechanism is not fully defined. Binding to synaptic-vesicle protein SV2A may contribute to altered vesicle exocytosis and antiseizure activity; the exact molecular significance remains uncertain.

IR absorption

Fast oral absorption; peak about 1 hour fasting,100% bioavailability. IR tablets and oral solution are bioequivalent; food delays/reduces peak without reducing extent.

XR absorption

Keppra XR peak about 4 hours; food can further delay it. A comparable daily exposure does not justify independent schedule substitution.

Binding / metabolism

< 10% protein-bound. Major inactive metabolite arises from non-CYP enzymatic hydrolysis.

Elimination / half-life

Approximately 66% excreted unchanged renally; adult half-life about 7 ± 1 hour, prolonged with renal impairment/older age.

Treatment implication

Renal function and formulation drive dosing; pregnancy and younger age can change clearance.

Track seizure control, adherence, mood/behavior, sedation and coordination. Assess renal function initially and as clinically warranted; recalculate adult BSA-adjusted CrCl and review weight-based pediatric doses. CBC is symptom-triggered per warning; monitor young-child diastolic BP. Pregnancy/postpartum warrants close seizure/level monitoring when appropriate. No universal therapeutic concentration or routine laboratory interval is supplied by these labels.

Do not stop or change IR/XR frequency independently. Report self-harm thoughts, major behavioral changes, fever/nodes/rash or allergic swelling/breathing difficulty urgently. Delay driving/hazardous activities until effects and seizure restrictions are understood. Use a calibrated oral syringe for solution; verify 100 mg/mL and per-dose mL. Follow whole-tablet restrictions and Spritam’s liquid-assisted dispersal. Discuss pregnancy/feeding plans, keep follow-up visits and check the medicine name/strength when refilled.

Ingredient / route

Levetiracetam 500 mg · immediate-release oral tablet.

Appearance / imprint

Yellow oblong scored film-coated tablet; ucb 500. Swallow whole.

Labeler / example NDC

UCB · 50474-595-40,120-tablet bottle.

U.S. status

Prescription NDA antiseizure product; no DEA schedule.

Keppra IR / solution

250,500,750,1000 mg tablets; 100 mg/mL grape-flavored solution. Example solution NDC 50474-001-48.

Keppra IV concentrate

500 mg/5 mL (100 mg/mL), single-use vial; dilute before 15-minute infusion. Example NDC 50474-002-63.

Keppra XR

500 and 750 mg whole extended-release tablets, UCB 500XR/UCB 750XR; 500 mg example NDC 50474-598-66.

Spritam

Current selected label lists 250 and 500 mg tablets for suspension in child-resistant blisters; no partial tablets or intact swallowing. Example 500 mg NDC 43485-102-60.

Elepsia XR

1000 and 1500 mg bilayer tablets with release portal, imprints 574/575; example 1000 mg NDC 80705-100-30. High strengths impose renal restrictions.

Other formulations

Other generic solutions, tablets or IV premixes require their own indication, age, concentration, preparation and storage label; no universal premix regimen inferred.

Keppra IR/solution/XR, selected IV and Spritam: store at 25°C, excursions 15–30°C. Elepsia XR: 20–25°C, excursions 15–30°C; dispense tight/light-resistant. Keep Spritam protected in intact blister until use, peel rather than push, and administer dispersions immediately. Selected IV diluted solution may be held no more than 4 hours at 15–30°C; inspect for particles/discoloration and discard unused vial contents. Follow pharmacist-prepared product requirements rather than extending concentrate stability to another premix.